Alpha1H given before surgery for low-grade, non-muscle invasive bladder cancer
Tests Alpha1H before bladder tumor surgery in adults with early bladder cancer.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
Key facts
- Where
- Prague, CzechiaSee the site
- Phase
- Phase 3
Where in Czechia
- Fakultni Nemocnice Motol a HomolkaPrague, CzechiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hamlet Pharma AB
- Trial code
- NCT07804056EU 2026-525531-16-00
- Record updated
- 21 September 2026
- Original description
The goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H.Read full original descriptionShow less
A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer
The goal of this clinical trial is to learn if the drug Alpha1H works to treat low-to-intermediate risk non-muscle-invasive bladder cancer in adults. It will also learn about the safety of drug Alpha1H.
The main questions it aims to answer are:
* Does giving drug Alpha1H before surgery lower the risk of cancer returning or worsening compared to standard care alone? * Is drug Alpha1H safe and well-tolerated by participants? Researchers will compare participants receiving drug Alpha1H before standard surgery to participants receiving standard care alone to see if drug Alpha1H lowers the risk of cancer returning or progressing.
Participants will:
* Be randomly assigned to receive either drug Alpha1H before surgery or standard care alone. * Receive drug Alpha1H directly into the bladder 6 times over about 1 month if assigned to the Alpha1H group. * Hold the liquid in the bladder for up to 2 hours during each visit. * Undergo standard surgery through the urethra (TURBT) to remove remaining tumor tissue. * Visit the clinic regularly for follow-up checkups (including bladder examinations and urine tests) to check if the cancer returns. * Fill out questionnaires about their quality of life.
Inclusion: Signed and dated informed consent; Low- or intermediate-risk non-muscle-invasive bladder cancer (NMIBC) meeting one of the following definitions:; Low-risk NMIBC: Primary, solitary, Ta, low-grade, 0.5 cm to 3 cm; Intermediate-risk NMIBC (low-to-intermediate risk subgroup per IBCG classification):; Primary multifocal (<10 lesions), Ta, low-grade, 0.5 cm to 3 cm; Recurrent solitary, Ta, low-grade, 0.5 cm to 3 cm; or; Recurrent multifocal (<10 lesions), Ta, low-grade, >1 year after previous recurrence; Men and women aged 18 years or older; Negative pregnancy test at screening for women of childbearing potential; Women of childbearing potential must agree to use highly effective contraception methods throughout study participation; men of childbearing potential must refrain from donating sperm during the study; Ability to retain bladder contents for 2 hours.
Exclusion: Previous history of T1 or high-grade disease in recurrent tumors; Previous intravesical BCG immunotherapy; Prior radiotherapy or systemic chemotherapy; Any other investigational agent or non-marketed product within one month prior to Visit 1 and during the trial; Any concurrent illness that may render a participant ineligible or limit compliance with study requirements; Previously enrolled in this trial; Patients with T1 or high-grade non-muscle invasive papillary bladder cancer (NMIBC); Patients with any other cancer diagnosis within the last 5 years (except for skin basalioma); Acute urinary tract infection requiring antibiotic treatment; Known active HIV infection, defined as detectable HIV viral load at screening; Active hepatitis B virus (HBV) infection, defined as hepatitis B surface antigen (HBsAg) positivity with detectable HBV DNA at screening; Active hepatitis C virus (HCV) infection, defined as anti-HCV antibody positivity with detectable HCV RNA at screening in a patient not on stable antiviral treatment; Patient with non-papillary tumor appearance at the time of initial cystoscopy; WHO performance status of 3 or 4.